Yes. T-Booster is a compounded prescription oral capsule available only pursuant to a valid prescription from a licensed healthcare provider. A telehealth consultation, baseline laboratory evaluation (including serum testosterone, estradiol, LH, FSH), and medical intake are required to confirm hypogonadism diagnosis, establish candidacy, and determine appropriate dosing.

Common side effects associated primarily with enclomiphene include headache, nausea, and visual disturbances such as blurring or light sensitivity — these are typically dose-dependent and reversible. Estrogenic side effects including gynecomastia, bloating, and mood fluctuations may occur, particularly in men with higher aromatase activity. Zinc's natural aromatase-inhibiting properties help mitigate excess estrogen conversion. Report any persistent visual changes, unusual hormonal symptoms, or other unexpected effects to your provider promptly.

T-Booster is formulated for adult men with laboratory-confirmed hypogonadism. It is not appropriate for women who are pregnant or may become pregnant, as the enclomiphene component carries teratogenic risk. Patients with a history of hormone-sensitive malignancies including prostate cancer require oncological evaluation before use. Men with active or uncontrolled cardiovascular disease, significant hepatic impairment, or elevated baseline estradiol require individualized evaluation. All eligibility is determined by a licensed provider based on laboratory findings, symptom review, and complete health history.

Enclomiphene works by modulating the hypothalamic-pituitary-gonadal (HPG) axis; concurrent use of exogenous testosterone, anabolic steroids, or other hormone therapies will directly antagonize its mechanism and is contraindicated without explicit provider direction. Patients on anticoagulants should be monitored, as estrogen-modulating agents can influence coagulation parameters. Medications that affect hepatic CYP3A4 enzyme activity may alter enclomiphene metabolism. Always provide a complete medication list before beginning treatment.

Patients with a history of hormone-sensitive malignancy must not use this formulation without thorough oncological review. Those with cardiovascular disease, hepatic conditions, or a history of thromboembolic events require individualized provider evaluation. Men with fertility-related conditions or actively trying to conceive should discuss timing and protocol structure carefully with their prescriber. Regular laboratory monitoring — testosterone, estradiol, LH, FSH, and metabolic panel — is standard of care throughout treatment.